Short answer
ADC Therapeutics SA (ADCT) filed its Q1 2026 10-Q quarterly report on May 4, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $20M (up 15.1% year over year) with net income of −$33M.
Q1 2026 key financials · XBRL
- Revenue
- $20M
- +15.1% YoY
- Net income
- −$33M
- +14.6% YoY
- Operating margin
- -126.0%
- EPS (diluted)
- −$0.21
- +41.7% YoY
Source: XBRL data from the ADC Therapeutics SA (ADCT) Q1 2026 10-Q on SEC EDGAR. USD.
ADC Therapeutics SA Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $20.851M, down 9.5% YoY from $23.033M
- Product revenue $20.033M, up 15.1% YoY from $17.404M
- License revenue and royalties $0.818M, down 85.5% YoY from $5.629M
- Operating loss $25.245M vs $28.464M; net loss $32.968M vs $38.602M
- R&D expense $19.877M, down 31.3%; selling and marketing $12.708M, up 20.4%
Risk Factors
- No material changes to risk factors previously disclosed in the Annual Report
- No newly triggered risk factor identified for the quarter
- No material regulatory, legal, or compliance risk update disclosed
- No new operational, competitive, market, liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ADC Therapeutics SA quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.